Lyell Immunopharma, Inc. (LYEL) — Total Assets
| Fiscal Year | Total Assets | Change YoY |
|---|---|---|
| 2025 | $340.05M | -30.7% |
| 2024 | $490.86M | -34.6% |
| 2023 | $750.03M | -20.0% |
| 2022 | $937.56M | -16.8% |
| 2021 | $1.13B | +24.1% |
| 2020 | $908.28M | — |
| Fiscal Year | Total Assets | Change YoY |
|---|---|---|
| 2025 | $340.05M | -30.7% |
| 2024 | $490.86M | -34.6% |
| 2023 | $750.03M | -20.0% |
| 2022 | $937.56M | -16.8% |
| 2021 | $1.13B | +24.1% |
| 2020 | $908.28M | — |